Basel, Switzerland, 3 December 2012– A new study shows that ResistAid™, Lonza’s proprietary immune ingredient, has very good tolerability. The double-blind, randomized, placebo-controlled clinical trial was published in the November issue of the Food and Nutrition Sciences (Vol. 3, No. 11, p. 1533-1538), and can be found at the following url: http://www.scirp.org/journal/PaperInformation.aspx?paperID=24490
Conducted by analyze & realize AG, the study interviewed a total of 199 healthy participants, who received either 4.5g ResistAid™ or placebo for a 12 week period. To examine tolerability based on safety parameters, the research recorded the number of adverse events and changes in various clinical and laboratory parameters, as well as the global evaluation of tolerability by investigators and subjects, as compared to placebo.
“The tolerability was rated as “very good” or “good” by the investigators for 99 percent of the subjects, and by 98 percent of subjects in self-assessment with no statistical differences to placebo,” says Barbara Grube, M.D., coordinating investigator and lead author of the study. “There were no differences concerning the incidence of adverse events between the two groups. Therefore, the intake of ResistAid™ over a period of 12 weeks can be considered as safe as placebo. “
ResistAid™ is a natural immune support ingredient extracted from North American larch trees, consisting of larch arabinogalactan and bioactive polyphenols. It has a number of technical properties, which make it formulation-friendly in applications such as dietary supplements and functional foods. ResistAid™ can be used in standalone form or combined with other products to increase functionality. It is self-affirmed GRAS with notification provided to the U.S. Food and Drug Administration.